Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Today, a new ESC Clinical Consensus Statement published in the European Heart Journal discusses the key role of vaccination ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Export volumes have been lower so far this year, but higher sales prices have more than made up for lower volumes.

New research uses bird droppings to track avian flu in remote regions, revealing hidden hotspots and potential for early ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...